Compass Pathways Clears Another Hurdle – Builds Stronger FDA Case For Its Much-Awaited Depression Therapy
Among patients receiving a 25 mg dose, 39% achieved a clinically meaningful reduction in depression symptoms by Week…
Compass Pathways soars as psilocybin depression treatment hits second Phase 3 trial goals – Endpoints News
Compass Pathways soars as psilocybin depression treatment hits second Phase 3 trial goals Endpoints NewsBREAKING: Second Positive Phase 3…